(Bold for FDA approved)
• Binds to benzodiazepine receptors at the GABA-A ligand-gated chloride channel complex
• Enhances the inhibitory effects of GABA
• Boosts chloride conductance through GABA-regulated channels
• Inhibitory actions in sleep centers may provide sedative hypnotic effects
• Generally takes effect in less than an hour
• Sedation, fatigue, depression
• Dizziness, ataxia, slurred speech, weakness
• Forgetfulness, confusion
• Hyperexcitability, nervousness
• Rare hallucinations, mania
• Rare hypotension
• Hypersalivation, dry mouth
• Rebound insomnia when withdrawing from long-term treatment
• Respiratory depression, especially when taken with CNS depressants in overdose
• Rare hepatic dysfunction, renal dysfunction, blood dyscrasias
unusual
common
• Wait
• To avoid problems with memory, only take flurazepam if planning to have a full night’s sleep
• Lower the dose
• Switch to a shorter-acting sedative hypnotic
• Switch to a non-benzodiazepine hypnotic
• Administer flumazenil if side effects are severe or life-threatening
• 15–30 mg/day at bedtime for 7–10 days
• Capsule 15 mg, 30 mg
• Not generally intended for long-term use
• Because of its relatively longer half-life, flurazepam may cause some daytime sedation and/or impaired motor/cognitive function, and may do so progressively over time
• Flurazepam is a Schedule IV drug
• Some patients may develop dependence and/or tolerance; risk may be greater with higher doses
• History of drug addiction may increase risk of dependence
• Recommended dose: 15 mg/day
• Recommended dose: 15 mg/day
• Benzodiazepines have been used to treat insomnia associated with acute myocardial infarction
• Recommended dose: 15 mg/day
• Safety and efficacy have not been established
• Long-term effects of flurazepam in children/adolescents are unknown
• Should generally receive lower doses and be more closely monitored
• Contraindicated for use in pregnancy
• Effective June 30, 2015, the FDA requires changes to the content and format of pregnancy and lactation information in prescription drug labels, including the elimination of the pregnancy letter categories; the Pregnancy and Lactation Labeling Rule (PLLR or final rule) applies only to prescription drugs and will be phased in gradually for drugs approved on or after June 30, 2001
• Infants whose mothers received a benzodiazepine late in pregnancy may experience withdrawal effects
• Neonatal flaccidity has been reported in infants whose mothers took a benzodiazepine during pregnancy
• Unknown if flurazepam is secreted in human breast milk, but all psychotropics are assumed to be secreted in breast milk
• Recommended either to discontinue drug or bottle feed
• Effects on infant have been observed and include feeding difficulties, sedation, and weight loss
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera